Laura Hughes is a Rheumatology/Immunology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 Pepperell Pkwy
Opelika, AL 368015452
Telephone
334-528-6610Provider last certified this registry record 17 Aug 2021.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202524 payments
- AstraZeneca Pharmaceuticals LPProgram year202514 payments
- Janssen Biotech, Inc.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.8%Folate Analog Metabolic Inhibitor10.6%Methotrexate94%Rasuvo6%Part D<11 patientsNonsteroidal Anti-inflammatory Drug6.3%Celecoxib100%Part D≥39 patients+ 9 more classes in this area
Metabolism & gastrointestinal
17.4%Corticosteroid13%Prednisone100%Part D≥102 patientsProton pump inhibitor1.8%Omeprazole69%Pantoprazole Sodium31%Part D<11 patients+ 3 more classes in this area
Nervous system
17.4%Gabapentinoids6.8%Gabapentin87%Pregabalin13%Part D<11 patientsOpioid Agonist3.4%Tramadol Hcl100%Part D≥20 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2005–2009 per NIH RePORTER. The latest:
- Pharmacogenetics of Methotrexate in Rheumatoid Arthritis
University of Alabama at Birmingham
FY2009$117,032K23AR052051 - Pharmacogenetics of Methotrexate in Rheumatoid Arthritis
University of Alabama at Birmingham
FY2008$114,468K23AR052051 - Pharmacogenetics of Methotrexate in Rheumatoid Arthritis
University of Alabama at Birmingham
FY2007$111,920K23AR052051
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”